[Updated] Notice of Partial Correction of Financial Results in FY2020 Earnings Presentation

On May 28, 2021 Kuraray Group reported that FY2020 Earnings Announcement Presentation disclosed on February 10, 2021 (Press release, Kuraray, MAY 28, 2021, https://pdf.irpocket.com/C3405/M6bm/Wxzm/BKYp.pdf [SID1234583266]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

1. Reason for correction
There was an error in the figures for CAPEX (Acceptance basis) for FY2020 in the sections on "Cash Flow for FY2020" (page 19) and "Forecast for FY2021" (page 22). There have been no changes to the previously disclosed Consolidated Financial Statements.

2. Correction details
Corrections have been made to the numbers circled in red.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!